Ramesh Mazhari, MD
Interventional Cardiology · Washington, DCNPI 1609913045
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 54.5% of the total. 2025 is the largest year on record at $19,855, more than ten times the $1,880 reported in 2019.
Across 266 payments — averaging $153.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$22K
- Abiomed$11K
- Abbott$4K
- Edwards Lifesciences$979
- Boston Scientific$845
- Terumo Medical Corporation$329
- plus $2K from 18 others
Across 2 payments — averaging $109.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$218
What the payments were for
- Consulting fees$4,20010%
- Grants$4,00010%
- Travel & lodging$22,71056%
- Food & beverage$9,78824%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 88 | $22,167 |
| Abiomed | 45 | $10,958 |
| Abbott | 24 | $3,773 |
| Edwards Lifesciences | 19 | $979 |
| Boston Scientific | 26 | $845 |
| Terumo Medical Corporation | 5 | $329 |
| Cardiovascular Systems Inc. | 17 | $284 |
| Inari Medical, Inc. | 3 | $261 |
| Amgen | 8 | $250 |
| Asahi Intecc USA, Inc. | 3 | $184 |
| Cook Medical LLC | 6 | $134 |
| Teleflex LLC | 3 | $91 |
| Novo Nordisk | 2 | $84 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $66 |
| Recor Medical Inc | 2 | $46 |
| Novartis | 2 | $45 |
| Angiodynamics, Inc. | 2 | $43 |
| Stryker | 2 | $40 |
| BD | 2 | $37 |
| W. L. Gore & Associates, Inc. | 1 | $22 |
| Shockwave Medical, Inc | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$10,785
- Impella$5,148
- NAVITOR$1,450
- Mitra Clip system$1,233
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$516
- MitraClip$461
- SYMPLICITY G3$323
- FLOWTRIEVER CATHETER, S$182
- CT THROMBECTOMY SYSTEM KIT$182
- METACROSS OTW$182
- DRAGONFLY OPSTAR$179
- ASAHI PTCA Guide Wire$128
- AngioJet Ultra 5000A$128
- Micra$101
How this compares
Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 102 | $127,713 |
| EntrestoSacubitril/Valsartan | 52 | $78,252 |
| EliquisApixaban | 50 | $61,632 |
| XareltoRivaroxaban | 19 | $20,962 |
| Rosuvastatin Calcium | 88 | $1,941 |
| Atorvastatin Calcium | 142 | $1,927 |
| Prasugrel Hcl | 23 | $1,911 |
| Metoprolol Succinate | 125 | $1,788 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 20 | $1,437 |
| Ezetimibe | 40 | $1,080 |
| ClopidogrelClopidogrel Bisulfate | 85 | $1,016 |
| Losartan Potassium | 70 | $777 |
| Ranolazine ErRanolazine | 11 | $624 |
| Valsartan | 18 | $588 |
| Amlodipine Besylate | 63 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $45 | $78,25252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Washington
- Ron WaksmanWashington$915K
- Toby RogersWashington$880K
- Augusto PichardWashington$180K
- Lowell SatlerWashington$112K
- Jonathan ReinerWashington$77K
- Brian CaseWashington$63K
- Horst SievertWashington$58K
- Nelson BernardoWashington$55K
- Itshac Ben-DorWashington$25K
- Nardos TemesgenWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.